Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 23, 2023 08:00 ET | Source: Windtree Therapeutics

Windtree Announces Issuance of Composition of Matter Patent for Dual Mechanism SERCA2a Activators by the US Patent and Trademark Office

WARRINGTON, Pa., Aug. 23, 2023 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing late-stage interventions...
August 07, 2023 16:05 ET | Source: Windtree Therapeutics

Windtree Therapeutics Reports Second Quarter 2023 Financial Results and Provides Key Business Updates

Company plans to initiate a Phase 2 SEISMiC extension study of istaroxime in early cardiogenic shock in Q3;Study start-up for a Phase 2 SCAI Stage C cardiogenic shock study underway Completed $12.4...
June 27, 2023 08:00 ET | Source: Windtree Therapeutics

Windtree Therapeutics Appoints Mark Strobeck, Ph.D. to Board of Directors

WARRINGTON, Pa., June 27, 2023 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing late-stage interventions...
June 12, 2023 08:00 ET | Source: Windtree Therapeutics

Windtree Announces Notice of Allowance from the US Patent and Trademark Office for a Group of SERCA2a Activators with a Dual Mechanism

WARRINGTON, Pa., June 12, 2023 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing late-stage interventions...
June 05, 2023 08:00 ET | Source: Windtree Therapeutics

Windtree Therapeutics to Host Virtual R&D and Investor Day Focusing on the Cardiogenic Shock Market, Istaroxime, Company Strategy and Planned Near-Term Milestones

Virtual event to take place on June 14, 2023 at 1:00 pm ET WARRINGTON, Pa., June 05, 2023 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or “the Company”) (NasdaqCM: WINT), a...
May 15, 2023 16:30 ET | Source: Windtree Therapeutics

Windtree Therapeutics Reports First Quarter 2023 Financial Results and Provides Key Business Updates

WARRINGTON, Pa., May 15, 2023 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or “the Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing late-stage interventions...
April 27, 2023 08:00 ET | Source: Windtree Therapeutics

Windtree Therapeutics Announces Publication from Its SEISMiC Pre Cardiogenic Shock Study Comparing Two Doses of Istaroxime

WARRINGTON, Pa., April 27, 2023 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT) is a biotechnology company focused on advancing late-stage...
April 24, 2023 16:01 ET | Source: Windtree Therapeutics

Windtree Therapeutics Announces Closing of $12.42 Million Underwritten Public Offering Including Full Exercise of Overallotment Option

WARRINGTON, Pa., April 24, 2023 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing late-stage interventions...
April 20, 2023 08:30 ET | Source: Windtree Therapeutics

Windtree Therapeutics Announces Pricing of Upsized $10.8 Million Underwritten Public Offering

WARRINGTON, Pa., April 20, 2023 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing late-stage interventions...
April 17, 2023 08:00 ET | Source: Windtree Therapeutics

Windtree Therapeutics Announces Issuance of New Dual Mechanism SERCA2a Activator Patent

WARRINGTON, Pa., April 17, 2023 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing late-stage interventions...